ArticleAntimicrobial agents and chemotherapy2004
TEM-121, a novel complex mutant of TEM-type beta-lactamase from Enterobacter aerogenes.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Population characteristics of pathogenicFrontiers in microbiology · 2024Article
- Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase fromACS infectious diseases · 2021Article
- Review
- Genomic and Virulence Characterization of Intrauterine PathogenicFrontiers in microbiology · 2018Article
- The MAST® D68C test: an interesting tool for detecting extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Article
- Computer aided screening of potent inhibitor compounds against inhibitor resistant TEM β-lactamase mutants from traditional Chinese medicine.Bioinformation · 2014Article
- TEM-187, a new extended-spectrum β-lactamase with weak activity in a Proteus mirabilis clinical strain.Antimicrobial agents and chemotherapy · 2013Article
- Virulence factors and TEM-type β-lactamases produced by two isolates of an epidemic Klebsiella pneumoniae strain.Antimicrobial agents and chemotherapy · 2012Article
- Characterization of the Novel CMT Enzyme TEM-154.Antimicrobial agents and chemotherapy · 2011Article
- International spread and persistence of TEM-24 is caused by the confluence of highly penetrating enterobacteriaceae clones and an IncA/C2 plasmid containing Tn1696::Tn1 and IS5075-Tn21.Antimicrobial agents and chemotherapy · 2010Article
- Functional analysis of insertion sequence ISAba1, responsible for genomic plasticity of Acinetobacter baumannii.Journal of bacteriology · 2009Article
- Cefepime: a reappraisal in an era of increasing antimicrobial resistance.Expert review of anti-infective therapy · 2008Review
- TEM-158 (CMT-9), a new member of the CMT-type extended-spectrum beta-lactamases.Antimicrobial agents and chemotherapy · 2007Article
- Evolution of TEM-type enzymes: biochemical and genetic characterization of two new complex mutant TEM enzymes, TEM-151 and TEM-152, from a single patient.Antimicrobial agents and chemotherapy · 2007Article
- CMT-type beta-lactamase TEM-125, an emerging problem for extended-spectrum beta-lactamase detection.Antimicrobial agents and chemotherapy · 2006Article
- TEM-109 (CMT-5), a natural complex mutant of TEM-1 beta-lactamase combining the amino acid substitutions of TEM-6 and TEM-33 (IRT-5).Antimicrobial agents and chemotherapy · 2005Article
- Extended-spectrum beta-lactamases: a clinical update.Clinical microbiology reviews · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterobacter aerogenes clinical isolate LOR was resistant to penicillins and ceftazidime but susceptible to cefuroxime, cephalothin, cefoxitin, cefotaxime, ceftriaxone, and cefepime. PCR and cloning experiments from this strain identified a novel TEM-type beta-lactamase (TEM-121) differing by five amino acid substitutions from beta-lactamase TEM-2 (Glu104Lys, Arg164Ser, Ala237Thr, Glu240Lys, and Arg244Ser) and by only one amino acid change from the extended-spectrum beta-lactamase (ESBL) TEM-24 (Arg244Ser), with the last substitution also being identified in the inhibitor-resistant beta-lactamase IRT-2. Kinetic parameters indicated that TEM-121 hydrolyzed ceftazidime and aztreonam (like TEM-24) and was inhibited weakly by clavulanic acid and strongly by tazobactam. Thus, TEM-121 is a novel complex mutant TEM beta-lactamase (CMT-4) combining the kinetic properties of an ESBL and an inhibitor-resistant TEM enzyme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.